Analyst Price Target is $16.33
▲ +304.29% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for NeuBase Therapeutics in the last 3 months. The average price target is $16.33, with a high forecast of $17.00 and a low forecast of $15.00. The average price target represents a 304.29% upside from the last price of $4.04.
Current Consensus is
The current consensus among 3 polled investment analysts is to buy stock in NeuBase Therapeutics. This Buy consensus rating has held steady for over two years.
NeuBase Therapeutics, Inc. is a biotechnology company. It engages in the development of drugs for patients with genetic neurological disorder. The firms pipelines include Huntington's Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA.